<DOC>
	<DOCNO>NCT00637351</DOCNO>
	<brief_summary>GSK Biologicals work development vaccine protect elderly people bacterial pneumonia . Diagnostic bacterial pneumonia difficult , future study project , would useful easy non invasive test . New clinical read-out need detect identify causative pathogen . These assay base specific antigen detection urine specific pathogen DNA detection blood . Technical clinical validation assay realise later stage sample come epidemiological and/or phase III study . To allow development test GSK Biologicals laboratory , urine blood sample need subject age 65 diagnose pneumonia . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</brief_summary>
	<brief_title>A Study Elderly Subjects With Pneumonia Support Development Bacteriological Diagnostic Assays</brief_title>
	<detailed_description />
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Streptococcal Infections</mesh_term>
	<criteria>Subjects investigator believe comply requirement protocol enrol study . A male female age 65 time study . Written inform consent obtain subject . Clinical pneumonia diagnose chest Xray detect within 7 day study entry . Vaccination pneumococcal Haemophilus vaccine within last 3 month study entry . Antibiotherapy start 7 day Screening . A negative culture Streptococcus pneumoniae NonTypable Haemophilus influenza . A urine sample Screening le 40 mL .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>